Fludarabine + Cyclophosphamide
Phase 1/2CompletedDevelopment Stage
Non-Hodgkin's Lymphoma, Relapsed
Non-Hodgkin's Lymphoma, Relapsed, Chronic Lymphoid Leukemia in Relapse, Non-Hodgkin's Lymphoma Refractory, Chronic Lymphocytic Leukemia, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-cell Chronic Lymphocytic Leukemia, B-cell Non Hodgkin Lymphoma, Small Lymphocytic Lymphoma
Mar 24, 2020 โ Jun 24, 2021
About Fludarabine + Cyclophosphamide
Fludarabine + Cyclophosphamide is a phase 1/2 stage product being developed by Precision BioSciences for Non-Hodgkin's Lymphoma, Relapsed. The current trial status is completed. This product is registered under clinical trial identifier NCT04030195. Target conditions include Non-Hodgkin's Lymphoma, Relapsed, Chronic Lymphoid Leukemia in Relapse, Non-Hodgkin's Lymphoma Refractory.
Hype Score Breakdown
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04030195 | Phase 1/2 | Completed |
Competing Products
20 competing products in Non-Hodgkin's Lymphoma, Relapsed
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| YM155 + Rituximab | Astellas Pharma | Phase 2 | 52 |
| Tazemetostat | Eisai | Phase 2 | 52 |
| ONTAK | Eisai | Phase 2 | 52 |
| Tazemetostat | Eisai | Phase 1 | 33 |
| ME-401 | Kyowa Kirin | Phase 1 | 33 |
| ME-401 | Kyowa Kirin | Phase 2 | 52 |
| gemcitabine | Eli Lilly | Phase 2 | 52 |
| gemcitabine + cisplatin + dexamethasone | Eli Lilly | Phase 2 | 52 |
| LY317615 | Eli Lilly | Phase 2 | 52 |
| LY4584180 + Rituximab | Eli Lilly | Phase 1 | 33 |
| Bortezomib + Rituximab + Rituximab | Johnson & Johnson | Phase 3 | 77 |
| HRS-3738 | Jiangsu Hengrui Medicine | Phase 1 | 33 |
| SHR1459 ๏ผYY-20394 + SHR1459 ๏ผYY-20394 + Gemcitabine-Oxaliplatin | Jiangsu Hengrui Medicine | Phase 2 | 52 |
| ABT-199 + Ketoconazole | AbbVie | Phase 1 | 33 |
| ABT-199 + Rifampin | AbbVie | Phase 1 | 33 |
| [14C]ABT-199 (GDC-0199) | AbbVie | Phase 1 | 33 |
| ABT-199 + Rituximab + Bendamustine | AbbVie | Phase 1 | 33 |
| ABBV-291 | AbbVie | Phase 1 | 33 |
| ABT-199 | AbbVie | Phase 1 | 33 |
| Avelumab | Merck | Phase 1 | 33 |